Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05144971 · ClinicalTrials.gov registry record
StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
A clinical trial of ESRD and Diabete Mellitus, sponsored by Nova Biomedical.
- Completed
- Registry status
- 175
- Enrollment target
- 1
- Study location
NCT05144971: Completed study of ESRD and Diabete Mellitus, sponsored by Nova Biomedical.
NCT05144971 is a study of ESRD and Diabete Mellitus that has completed, run by Nova Biomedical. The registered enrollment target is 175 participants, above the 127-participant average among 13 other ESRD trials with a reported enrollment target (38% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05144971, a study of ESRD and Diabete Mellitus, has completed, sponsored by Nova Biomedical.
- COMPLETED
- Registry status
- 175 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to assess the performance of the Nova StatStrip A Glucose/Creatinine Meter System in the hands of the subject (lay user) and compare the result to an accepted Glucose/Creatinine reference method in the hands of a trained technician.
Primary Outcome
The primary objective of this study is to assess the performance of the Nova StatStrip A Glucose/Creatinine Meter System in the hands of the subject (lay user) and compare the result to an accepted Glucose/Creatinine reference method in the hands of a trained technician. The two parameters for the outcome measure in this study are glucose and creatinine. The unit of measure for glucose and creatinine is mg/dL and mmol/L, respectively.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Glucose, Creatinine
Study Locations (1)
Florida
- Excellence Medical Research - Miami Gardens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2021-12-03 |
What the finished NCT05144971 record still lists
NCT05144971 is an observational study that tracks outcomes without assigning an intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 127-participant average among 13 other ESRD trials with a reported enrollment target (38% higher).
The record links to 3 conditions, with ESRD appearing as the primary indexed condition, and to 1 intervention - of which Glucose, Creatinine is the first listed.
NCT05144971 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05144971 about?
NCT05144971 is a clinical study titled "StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation". The primary objective of this study is to assess the performance of the Nova StatStrip A Glucose/Creatinine Meter System in the hands of the subject (lay user) and compare the result to an accepted Glucose/Creatinine reference method in the hands of a trained technician.
What is the current status of trial NCT05144971?
This trial is currently completed. The enrollment target is 175 participants. The study started on 2021-10-28. Estimated completion is 2021-12-03.
What conditions does trial NCT05144971 study?
This clinical trial studies the following conditions: ESRD, Diabete Mellitus, CKD.
What interventions are being tested in trial NCT05144971?
The interventions under investigation include: Glucose, Creatinine (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05144971?
This trial is sponsored by Nova Biomedical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05144971 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ESRD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05144971's enrollment target sits among peer trials
175 3rd of 13 higher than 11 of 13 other ESRD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ESRD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
SAfety of Regional Citrate Anticoagulation (SARCA Study)
RECRUITING · Phase 3
-
Adding Urea to the Final Dialysis Fluid
RECRUITING · Phase 1
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Repletion of Ergothioneine in Patients With Kidney Failure
RECRUITING · NA
-
Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI